Evolent Health (EVH) shares are soaring 7.19% in pre-market trading on Friday, as the company receives positive attention from Wall Street analysts. The healthcare technology firm's stock is gaining momentum following upbeat analyst reports and a price target increase.
UBS analyst Kevin Caliendo has raised the firm's price target on Evolent Health to $15 from $14, while maintaining a Buy rating on the shares. This upgrade represents increased confidence in the company's growth prospects and potential for value creation.
Additionally, TD Cowen analyst Charles Rhyee reaffirmed a Buy rating on Evolent Health, setting a price target of $14.00. The consistent positive sentiment from multiple analysts is likely contributing to investor enthusiasm and driving the stock's pre-market surge.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。